HHV8
MCID: HMN032
MIFTS: 53

Human Herpesvirus 8 (HHV8)

Categories: Cancer diseases

Aliases & Classifications for Human Herpesvirus 8

MalaCards integrated aliases for Human Herpesvirus 8:

Name: Human Herpesvirus 8 58
Human Herpesvirus 8, Susceptibility to 58 13
Hhv-8, Susceptibility to 58
Kaposi Sarcoma 74
Hhv8s 58
Hhv-8 58
Hhv8 49

Classifications:



External Ids:

OMIM 58 614836
UMLS 74 C0036220

Summaries for Human Herpesvirus 8

OMIM : 58 Human herpesvirus-8 (HHV-8) is the etiologic agent of Kaposi sarcoma, primary effusion lymphoma, and some forms of multicentric Castleman disease (Pedergnana et al., 2012). See 148000 for general phenotypic information on these diseases, as well as information on HHV-8-associated pathogenesis. (614836)

MalaCards based summary : Human Herpesvirus 8, also known as human herpesvirus 8, susceptibility to, is related to kaposi sarcoma and primary effusion lymphoma, and has symptoms including pruritus and exanthema. An important gene associated with Human Herpesvirus 8 is HHV8S (Human Herpesvirus 8, Susceptibility To), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Bleomycin and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include b cells, skin and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Human Herpesvirus 8

Diseases related to Human Herpesvirus 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 kaposi sarcoma 33.2 IL6 IL6ST IRF3
2 primary effusion lymphoma 30.8 BCL6 IL6
3 autoimmune lymphoproliferative syndrome, type v 30.3 BCL2 BCL6
4 human immunodeficiency virus type 1 30.2 HLA-A HLA-B HLA-C IL6 IRF3
5 acquired immunodeficiency syndrome 30.2 BCL6 HLA-B IL6
6 pityriasis rosea 30.1 HLA-A HLA-B HLA-C
7 multicentric castleman disease 30.1 BCL6 IL6
8 paraneoplastic pemphigus 30.0 HLA-A HLA-B HLA-C
9 castleman disease 29.8 BCL6 IL6 IL6R
10 immunodeficiency 16 11.1
11 sarcoma 11.0
12 lymphoma 10.6
13 myeloma, multiple 10.4
14 phenytoin or carbamazepine toxicity 10.4 HLA-A HLA-B
15 postherpetic neuralgia 10.4 HLA-A HLA-B
16 atrial tachyarrhythmia with short pr interval 10.3 HLA-A HLA-B
17 htlv-1 associated myelopathy/tropical spastic paraparesis 10.3 HLA-A HLA-B
18 pars planitis 10.3 HLA-A HLA-B
19 chronic pyelonephritis 10.3 HLA-A HLA-B
20 nontuberculous mycobacterial lung disease 10.3 HLA-A HLA-B
21 spindle cell sarcoma 10.3
22 histoplasmosis 10.3 HLA-A HLA-B
23 cytomegalovirus retinitis 10.2 HLA-A HLA-B
24 angiosarcoma 10.2
25 pemphigus 10.2
26 intermediate uveitis 10.2 HLA-B IL6
27 separation anxiety disorder 10.2 HLA-A HLA-B
28 hepatitis 10.2
29 leukemia 10.2
30 idiopathic bronchiectasis 10.2 HLA-A HLA-B HLA-C
31 alveolar echinococcosis 10.2 HLA-A HLA-B HLA-C
32 glaucomatocyclitic crisis 10.2 HLA-A HLA-B HLA-C
33 geographic tongue 10.2 HLA-A HLA-B HLA-C
34 stevens-johnson syndrome/toxic epidermal necrolysis 10.2 HLA-A HLA-B HLA-C
35 panuveitis 10.2 HLA-A HLA-B
36 severe cutaneous adverse reaction 10.2 HLA-A HLA-B HLA-C
37 anterior uveitis 10.2 HLA-A HLA-B IL6
38 aphthous stomatitis 10.2 HLA-A HLA-B IL6
39 prostate cancer 10.2
40 prostate cancer, hereditary, 8 10.2
41 prostate cancer, hereditary, 6 10.2
42 dengue hemorrhagic fever 10.2 HLA-A HLA-B IL6
43 takayasu arteritis 10.2 HLA-A HLA-B IL6
44 spondylitis 10.1 HLA-B HLA-C IL6
45 hepatitis c virus 10.1
46 pulmonary hypertension 10.1
47 hepatitis c 10.1
48 psoriatic arthritis 10.1 HLA-B HLA-C IL6
49 human immunodeficiency virus infectious disease 10.1
50 herpes simplex 10.1

Graphical network of the top 20 diseases related to Human Herpesvirus 8:



Diseases related to Human Herpesvirus 8

Symptoms & Phenotypes for Human Herpesvirus 8

Clinical features from OMIM:

614836

UMLS symptoms related to Human Herpesvirus 8:


pruritus, exanthema

GenomeRNAi Phenotypes related to Human Herpesvirus 8 according to GeneCards Suite gene sharing:

27 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.75 HLA-A HLA-B HLA-C
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.75 HLA-A HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.75 HLA-A HLA-B HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.75 HLA-C IL6R
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.75 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.75 HLA-A HLA-B HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.75 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.75 HLA-A HLA-B HLA-C
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.75 HLA-A HLA-B HLA-C IL6R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.75 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.75 HLA-A HLA-B HLA-C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.75 IL6R
13 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.75 HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.75 IL6R
15 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.75 HLA-A HLA-B HLA-C
16 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.75 HLA-A HLA-B HLA-C
17 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.75 HLA-C

MGI Mouse Phenotypes related to Human Herpesvirus 8:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.02 BCL2 IL6 IL6R IL6ST NOP53

Drugs & Therapeutics for Human Herpesvirus 8

Drugs for Human Herpesvirus 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
2
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
3
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
5
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 134678-17-4 60825
6
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
7
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
8
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
9
Emtricitabine Approved, Investigational Phase 4,Phase 3,Not Applicable 143491-57-0 60877
10
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
11
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3,Not Applicable 147127-20-6 464205
12
Valganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 175865-60-8 64147
13
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
14 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
19 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
20 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Not Applicable
22 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
23 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Not Applicable
24 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
25 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Not Applicable
26
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
27 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
28 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Atazanavir Sulfate Phase 4,Phase 3
30
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 54677470 5281106
31
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
32
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 441300 65140
33
Zidovudine Approved Phase 2, Phase 3,Phase 3,Phase 1 30516-87-1 35370
34
Daunorubicin Approved Phase 3,Phase 1 20830-81-3 30323
35
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
36
tannic acid Approved Phase 3 1401-55-4
37
Aldesleukin Approved Phase 3,Phase 2,Phase 1 110942-02-4, 85898-30-2
38
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
39
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
40
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
41
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
42 Antimitotic Agents Phase 3,Phase 2,Phase 1
43 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
44 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
45 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
46 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
47 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Cyclooxygenase Inhibitors Phase 3,Not Applicable
50 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 191)
# Name Status NCT ID Phase Drugs
1 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
2 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
3 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
4 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4 Valganciclovir
5 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
6 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
7 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
8 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
9 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
10 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
11 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
12 Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients Completed NCT00002445 Phase 3 IM862
13 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
14 A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
15 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
16 PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) Completed NCT01099579 Phase 3 Atazanavir powder;Ritonavir oral solution;Atazanavir capsules;Ritonavir capsules
17 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
18 Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Completed NCT01924286 Phase 3 Prednisone;Placebo
19 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
20 Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Recruiting NCT03092817 Phase 3 Dexamethasone
21 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma Active, not recruiting NCT01352117 Phase 3 efavirenz/emtricitabine/tenofovir disoproxil fumarate;etoposide
22 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Active, not recruiting NCT01435018 Phase 3 Etoposide (ET);Bleomycin and Vincristine (BV);Paclitaxel (PTX);Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
23 Mirasol Evaluation of Reduction in Infections Trial Not yet recruiting NCT03737669 Phase 3
24 Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma Unknown status NCT00003419 Phase 2
25 Suppression of Oral HHV8 Shedding With Valganciclovir Completed NCT00194467 Phase 2 valganciclovir;placebo
26 Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma Completed NCT01067690 Phase 2 Indinavir in association with Vinblastina +/- Bleomicina
27 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity Completed NCT01296815 Phase 2 Bevacizumab
28 Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT01057121 Phase 1, Phase 2 Lenalidomide
29 Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir Completed NCT00362310 Phase 2 indinavir
30 Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00064142 Phase 2 halofuginone hydrobromide
31 Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00019188 Phase 1, Phase 2 interleukin-12
32 Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients Completed NCT00055237 Phase 2
33 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma Completed NCT02029430 Phase 2 aldoxorubicin
34 Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma Completed NCT00295984 Phase 2 nicotine
35 BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00024024 Phase 1, Phase 2 rebimastat
36 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00090987 Phase 2 imatinib mesylate
37 SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00005042 Phase 2 semaxanib
38 Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT Completed NCT02201420 Phase 2 Tc 99m tilmanocept
39 Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection Completed NCT00019240 Phase 2 cidofovir
40 Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma Completed NCT00019123 Phase 2 thalidomide
41 Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00003008 Phase 2 indinavir sulfate;nelfinavir mesylate;paclitaxel;ritonavir;saquinavir mesylate
42 Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00020449 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
43 A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002188 Phase 2 Alitretinoin
44 A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma Completed NCT00002131 Phase 2 Vesnarinone
45 The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma Completed NCT00002366 Phase 2 Ritonavir
46 A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002212 Phase 2 Bexarotene
47 Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma Completed NCT00002259 Phase 2 Mitoxantrone hydrochloride
48 The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma Completed NCT00001114 Phase 2 Interferon alfa-2b;Didanosine
49 SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment Completed NCT00005931 Phase 2 SU5416
50 Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. Completed NCT00002167 Phase 2 Tin ethyl etiopurpurin

Search NIH Clinical Center for Human Herpesvirus 8

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Human Herpesvirus 8

Anatomical Context for Human Herpesvirus 8

MalaCards organs/tissues related to Human Herpesvirus 8:

42
B Cells, Skin, T Cells, Liver, Endothelial, Kidney, Prostate

Publications for Human Herpesvirus 8

Articles related to Human Herpesvirus 8:

(show top 50) (show all 1137)
# Title Authors Year
1
Unusual case of human herpesvirus 8-positive large B-cell lymphoma associated with Castleman disease. ( 30899504 )
2019
2
Contribution of Human Herpesvirus 8 and Herpes Simplex Type 2 to Progression of Carotid Intima-Media Thickness in People Living With HIV. ( 30815506 )
2019
3
Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 associated lymphoproliferative disorders. ( 30610029 )
2019
4
Pediatric post-transplant hepatic kaposi sarcoma due to donor-derived human herpesvirus 8. ( 30843320 )
2019
5
Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8. ( 30888817 )
2019
6
No detectable human herpesvirus-8 oral shedding in seronegative-healthy, immunocompetent individuals from non-endemic regions for Kaposi's sarcoma: A pilot study. ( 28631891 )
2018
7
Seroprevalence of human herpesvirus 8 and its impact on the hemoglobin level in patients of end stage of renal diseases. ( 28876458 )
2018
8
Global epidemiology of human herpesvirus 8 in men who have sex with men: A systematic review and meta-analysis. ( 28975631 )
2018
9
Human Herpesvirus 8 in Perinatally HIV-infected Children with Interstitial Lung Disease. ( 29165615 )
2018
10
Kaposi sarcoma presenting shortly after primary infection by HIV and human herpesvirus-8. ( 29256918 )
2018
11
The unholy trinity of human herpesvirus 8-associated malignancy in a person living with HIV-1. ( 29309348 )
2018
12
Human Herpesvirus 8-Associated Inflammatory Cytokine Syndrome. ( 29322174 )
2018
13
Human Herpesvirus 8 Interferon Regulatory Factors 1 and 3 Mediate Replication and Latency Activities via Interactions with USP7 Deubiquitinase. ( 29343584 )
2018
14
Omega-3 decreases IL-6 levels in HIV and human herpesvirus-8 coinfected patients in Uganda. ( 29381560 )
2018
15
Kaposi sarcoma-associated herpesvirus/human herpesvirus 8-associated extracavitary primary effusion lymphoma presenting as multiple lymphomatous polyposis. ( 29505765 )
2018
16
Human herpesvirus 8 infection DNA positivity is associated with low insulin secretion: A case-control study in a sub-Saharan African population with diabetes. ( 29707905 )
2018
17
Peroxisomes support human herpesvirus 8 latency by stabilizing the viral oncogenic protein vFLIP via the MAVS-TRAF complex. ( 29746593 )
2018
18
Successful treatment of primary donor-derived human herpesvirus-8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient. ( 30014622 )
2018
19
DETECTION OF HUMAN HERPESVIRUS-8 ANTIGEN IN HIV-INFECTED PATIENTS IN EAST JAVA, INDONESIA. ( 30109285 )
2018
20
Human Herpesvirus 8 and Lymphoproliferative Disorders. ( 30416693 )
2018
21
Human herpesvirus 8 DNA detection and variant analysis in patients with multiple sclerosis. ( 30539059 )
2018
22
Insulin-like Growth Factor 2 Receptor Expression is Promoted by Human Herpesvirus 8-Encoded Interleukin-6 and Contributes to Viral Latency and Productive Replication. ( 30541844 )
2018
23
Cytomegalovirus, Epstein-Barr virus and human herpesvirus 8 salivary shedding in HIV positive men who have sex with men with controlled and uncontrolled plasma HIV viremia: a 24-month longitudinal study. ( 30567494 )
2018
24
Diagnosis of a rare cardiac human herpesvirus-8 positive B-cell lymphoma manifestation: a case report of a transoesophageal echocardiography-guided trans-septal catheter biopsy. ( 31020117 )
2018
25
Human herpesvirus-8 and human cytomegalovirus infections in Bowen's disease: Is there any association? ( 28366922 )
2017
26
Developmental Therapeutics Implications of Next-Generation Sequencing in Human Herpesvirus 8-Negative Castleman Disease. ( 28241212 )
2017
27
Human herpesvirus-8 positive iatrogenic Kaposi's sarcoma in the setting of refractory ulcerative colitis. ( 29291200 )
2017
28
Development of Kaposi sarcoma and hemophagocytic lymphohistiocytosis associated with human herpesvirus 8 in a renal transplant recipient. ( 26842102 )
2017
29
High seroprevalence of human herpesvirus 8 and herpes simplex virus 2 infections in men who have sex with men in Shanghai, China. ( 27769110 )
2017
30
Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone. ( 27283030 )
2017
31
Molecular typing of human herpesvirus 8 among HIV positive in comparison to HIV-negative individuals in Iran. ( 27463857 )
2017
32
Human herpesvirus 8 infection contributes to a T helper 2 immune response in men from Tobago with prostate cancer. ( 27734534 )
2017
33
High Prevalence of Human Herpesvirus 8 Infection in Diabetes Type 2 Patients and Detection of a New Virus Subtype. ( 27864801 )
2017
34
Talc pleurodesis allows long-term remission in HIV-unrelated Human Herpesvirus 8-associated primary effusion lymphoma. ( 28084853 )
2017
35
Elevated Serum PSA is Associated With Human Herpesvirus 8 Infection and Increased Circulating Cytokine Levels in Men From Tobago. ( 28117495 )
2017
36
Use of plasma human herpesvirus-8 viral load measurement: evaluation of practice in three UK HIV treatment centres. ( 28120699 )
2017
37
Regulatory T Cell Effect on CD8+ T Cell Responses to Human Herpesvirus 8 Infection and Development of Kaposi's Sarcoma. ( 28121161 )
2017
38
Cross-sectional and longitudinal investigation of human herpesvirus 8 seroprevalence in HIV-1-infected individuals in Osaka, Japan. ( 28131739 )
2017
39
Prevalence of Human Herpesvirus-8 and BK Polyoma Virus Infections in End-stage Renal Disease and the Influence of Renal Transplantation. ( 28340807 )
2017
40
Successful Treatment of Kaposi Sarcoma-Associated Herpesvirus Inflammatory Cytokine Syndrome After Kidney-Liver Transplant: Correlations With the Human Herpesvirus 8 miRNome and Specific T Cell Response. ( 28489271 )
2017
41
Human herpesvirus 8-related diseases: Histopathologic diagnosis and disease mechanisms. ( 28502522 )
2017
42
High Seroprevalence of Human Herpesvirus 8 Infection in HIV-positive Homosexual Men in Jiangsu Province, China. ( 28606034 )
2017
43
Diversity of human herpesvirus 8 genotypes in patients with AIDS and non-AIDS associated Kaposi's sarcoma, Castleman's disease and primary effusion lymphoma in Argentina. ( 28617968 )
2017
44
Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma. ( 28649271 )
2017
45
De Novo Human Herpesvirus 8 Tumors Induced by Rituximab in Autoimmune or Inflammatory Systemic Diseases. ( 28719723 )
2017
46
Human Herpesvirus 8 Infects and Replicates in Langerhans Cells and Interstitial Dermal Dendritic Cells and Impairs Their Function. ( 28768873 )
2017
47
Human Herpesvirus 8 Interleukin-6 Interacts with Calnexin Cycle Components and Promotes Protein Folding. ( 28878084 )
2017
48
Presence of human herpesvirus 8 (HHV-8) DNA sequences in patients with lymphoproliferative diseases and chronic blood disorders. ( 28916317 )
2017
49
Association of Household Food- and Drink-Sharing Practices With Human Herpesvirus 8 Seroconversion in a Cohort of Zambian Children. ( 28961804 )
2017
50
High Prevalence of Distinct Human Herpesvirus 8 Contributes to the High Incidence of Non-acquired Immune Deficiency Syndrome-Associated Kaposi's Sarcoma in Isolated Japanese Islands. ( 28968717 )
2017

Variations for Human Herpesvirus 8

Expression for Human Herpesvirus 8

Search GEO for disease gene expression data for Human Herpesvirus 8.

Pathways for Human Herpesvirus 8

Pathways related to Human Herpesvirus 8 according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 BCL2 BCL6 HLA-A HLA-B HLA-C IL6
2
Show member pathways
12.72 BCL2 BCL6 HLA-A HLA-B HLA-C IL6
3
Show member pathways
12.69 HLA-A HLA-B HLA-C IL6
4 12.66 BCL2 IL6 IL6R IL6ST
5
Show member pathways
12.53 BCL2 HLA-A HLA-B HLA-C IL6 IL6R
6
Show member pathways
12.42 BCL2 IL6 IL6R IL6ST
7
Show member pathways
12.35 HLA-A HLA-B HLA-C IRF3
8
Show member pathways
12.21 BCL2 IL6 IL6R IL6ST
9 12.17 HLA-A HLA-B HLA-C IL6
10
Show member pathways
12.15 IL6 IL6R IL6ST
11
Show member pathways
12.04 HLA-A HLA-B HLA-C IL6 IRF3
12
Show member pathways
12.02 BCL2 HLA-A HLA-B HLA-C IL6 IL6R
13 11.99 HLA-A HLA-B HLA-C
14 11.98 HLA-A HLA-B HLA-C IL6
15 11.97 BCL2 IL6R IL6ST
16
Show member pathways
11.96 IL6 IL6R IL6ST
17 11.96 HLA-A HLA-B HLA-C
18 11.96 HLA-A HLA-B HLA-C IL6ST IRF3
19 11.91 HLA-A HLA-B HLA-C
20
Show member pathways
11.89 IL6 IL6R IL6ST
21 11.75 BCL2 IL6 IL6R
22 11.73 BCL2 BCL6 IL6 IL6R
23 11.71 IL6 IL6R IL6ST
24
Show member pathways
11.71 IL6 IL6R IL6ST
25 11.65 BCL2 IL6 IL6R IL6ST
26
Show member pathways
11.45 IL6 IL6R IL6ST
27
Show member pathways
11.29 IL6 IL6R IL6ST
28 11.15 IL6 IL6R IL6ST
29 10.98 HLA-A HLA-B HLA-C
30 10.89 BCL2 IL6

GO Terms for Human Herpesvirus 8

Cellular components related to Human Herpesvirus 8 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 early endosome membrane GO:0031901 9.61 HLA-A HLA-B HLA-C
2 recycling endosome membrane GO:0055038 9.58 HLA-A HLA-B HLA-C
3 phagocytic vesicle membrane GO:0030670 9.54 HLA-A HLA-B HLA-C
4 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-A HLA-B HLA-C
5 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-A HLA-B HLA-C
6 ciliary neurotrophic factor receptor complex GO:0070110 9.26 IL6R IL6ST
7 MHC class I protein complex GO:0042612 9.13 HLA-A HLA-B HLA-C
8 interleukin-6 receptor complex GO:0005896 8.8 IL6 IL6R IL6ST

Biological processes related to Human Herpesvirus 8 according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.97 BCL6 HLA-A HLA-B HLA-C IRF3
2 negative regulation of apoptotic process GO:0043066 9.93 BCL2 BCL6 IL6 IL6ST
3 positive regulation of cell proliferation GO:0008284 9.93 BCL2 IL6 IL6R IL6ST
4 immune response GO:0006955 9.91 HLA-A HLA-B HLA-C IL6
5 cellular response to DNA damage stimulus GO:0006974 9.91 BCL2 BCL6 IRF3 NOP53
6 regulation of immune response GO:0050776 9.81 BCL6 HLA-A HLA-B HLA-C
7 defense response to virus GO:0051607 9.8 BCL2 IL6 IRF3
8 cytokine-mediated signaling pathway GO:0019221 9.77 BCL2 BCL6 IL6 IL6R IL6ST
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 IL6 IL6R IL6ST
10 positive regulation of osteoblast differentiation GO:0045669 9.72 IL6 IL6R IL6ST
11 response to cytokine GO:0034097 9.71 BCL2 IL6R IL6ST
12 antigen processing and presentation GO:0019882 9.67 HLA-A HLA-B HLA-C
13 acute-phase response GO:0006953 9.64 IL6 IL6R
14 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.63 HLA-A HLA-B HLA-C
15 endocrine pancreas development GO:0031018 9.62 IL6 IL6R
16 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.61 HLA-A HLA-B HLA-C
17 positive regulation of chemokine production GO:0032722 9.6 IL6 IL6R
18 positive regulation of acute inflammatory response GO:0002675 9.59 IL6 IL6ST
19 positive regulation of leukocyte chemotaxis GO:0002690 9.58 IL6 IL6R
20 positive regulation of T cell mediated cytotoxicity GO:0001916 9.58 HLA-A HLA-B HLA-C
21 ciliary neurotrophic factor-mediated signaling pathway GO:0070120 9.56 IL6R IL6ST
22 interferon-gamma-mediated signaling pathway GO:0060333 9.56 HLA-A HLA-B HLA-C IRF3
23 protection from natural killer cell mediated cytotoxicity GO:0042270 9.52 HLA-A HLA-B
24 interleukin-6-mediated signaling pathway GO:0070102 9.5 IL6 IL6R IL6ST
25 hepatic immune response GO:0002384 9.48 IL6 IL6R
26 type I interferon signaling pathway GO:0060337 9.46 HLA-A HLA-B HLA-C IRF3
27 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.13 HLA-A HLA-B HLA-C
28 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 8.8 HLA-A HLA-B HLA-C

Molecular functions related to Human Herpesvirus 8 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.43 HLA-A HLA-B HLA-C
2 ciliary neurotrophic factor receptor activity GO:0004897 9.32 IL6R IL6ST
3 interleukin-6 binding GO:0019981 9.16 IL6R IL6ST
4 interleukin-6 receptor activity GO:0004915 8.96 IL6R IL6ST
5 interleukin-6 receptor binding GO:0005138 8.8 IL6 IL6R IL6ST
6 protein binding GO:0005515 10.11 BCL2 BCL6 HLA-A HLA-B HLA-C IL6

Sources for Human Herpesvirus 8

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....